In this episode of the Psychedelic Spotlight podcast, we have the distinct privilege of speaking with one of the foremost experts in ketamine-assisted therapy, Dr. Steven L. Mandel, Founder and President of Ketamine Clinics Los Angeles.
Similar Posts
Healing Maps: From Ketamine Clinics to Psychedelic Retreats | The Yelp of Psychedelic Therapies
In today’s episode, Psychedelic Spotlight sits down with the founders…
Interview With Dr. Hyder A. Khoja
In this episode, Global Trac Solution’s CEO, David Flores, sits down with Dr. Hyder A. Khoja to learn more about the work they’re doing at Transcendent Therapeutics Inc.
MindMed 2021 Year-End Conference Call and Earnings: Big Updates for MNMD Stock
MindMed 2021 Year-End Conference Call and Earnings: Big Updates for MNMD Stock
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psychedelic-news/industry/
All Psychedelic Stock investors should take the time to listen to the conference calls of the companies they are investing in. That is doubly important for year-end calls, as often information is divulged on the direction of the company. If you are invested in MNMD or MMED stock, you need to listen to this call.
Follow us on Twitter:
The Psychedelic Investor: @psycInvestor
James: @Psy_Invest
Maria: @psy_holy
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Meet Kevin O’Leary, Rober Barrow, Daniel Carcillo and other psychedelic leaders @ the Benzinga Psychedelics Capital Conference.on April 19 @ Fontainebleau Hotel, Miami!
https://www.eventbrite.com/e/benzinga-psychedelics-capital-conference-spring-2022-tickets-238697028237?discount=PSYCHSPOTLIGHT15&fbclid=IwAR3tJFhoVfVWZvAyQuWSLEo3kJSmaq8VGnQQPz04NMhG3g7rHtSmRSAUq64
COUPON CODE: PSYCHSPOTLIGHT15
Interested in going to Malta for Plant Medicine Week April 5th-8th? Get discounted tickets here: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC
In this MindMed 2021 conference and earnings call, we gained important insights into the company’s many projects. These include: Project Lucy, which attempts to treat Anxiety using LSD; Project Angie, attempting to treat pain with LSD; Project Layla, attempting to treat addiction with 18-MC, and much more.
The company gives some updates on the science of psychedelics, as well as their hiring strategy and financial updates. MindMed is a company working on treating mental health conditions with psychedelics. They are a leading player in the shroom boom, and they aim to commercialize psychedelics as medicines.
Some of the questions MindMed is trying to answer are:
Can Psychedelics treat Mental Health conditions?
Can Psychedelics treat depression?
Can Psychedelics treat anxiety?
Can Psychedelics treat ADHD?
Can Psychedelics help with Autism?
Can Psychedelics help treat pain?
#MindMed #MNMD #MindMedStocks
MindMed Raises $19.5 Million // What Does This Mean for MMEDF/MMED? [Plus Upcoming Market CRASH?]
Hey guys! Today’s episode is more of a fast rant on the recent press release about MindMed raising ANOTHER $19.5M from Canaccord Genuity Corp, on a deal that is set to close tomorrow, March 9th.
Here, I’m discussing:
1. The number MindMed shares being sold and their respective price;
2.Why is MindMed doing this?
3. Potential short term and long term effects on MMED’s stock price
4. Nasdaq uplisting?
5. Market crash thoughts
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #MMEDNews
California COWARDS Delay Psychedelics Decriminalization Bill (I’m Pissed)
What’s up psychedelic investors! Today’s episode is mostly a RANT about how the California cowards delayed the psychedelics decriminalization bill until NEXT YEAR, their reason being that their LEADERS ARE NOT “EDUCATED” enough on the matter at hand…😤
Enjoy my 11 minute rant!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#californiapsychedelicsbill #californiabill #psychedelicstocks
MindMed Stock Catalysts for 2021: NASDAQ, Clinical Trial Results and More (MMED / MMEDF)
In today’s episode, we discuss :MindMed Stock Catalysts for 2021: NASDAQ, Clinical Trial Results and More (MMED / MMEDF).
2020 was a wild year for MindMed, with the company IPOing in March, at just over 20c/ share, all prices in American currency. Then, the MindMed stock price shot up to a high of $4.37 in December, only to fall about 30% and consolidate around $3 a share in the new year.
But what will be the main catalysts for MindMed and its stock going forward in 2021? Put another way, what are the events and dates that shareholders and potential investors should circle on their calendars?
In this episode, we are going to talk about several catalysts to look out for
1. MindMed’s Nasdaq uplisting
– When to expect MindMed to join the Nasdaq?
– Is MindMed’s uplisting a sure thing?
-What will happen to MindMed stock if/when the company gets uplisted?
2. Clinical trials wrapping up, and data being released by MindMed
– Important dates MindMed investors should circle in their calendars
3. MindMed’s quarter end financial reporting
4. MindMed conference calls
Unknown Catalysts for Mindmed:
1. Clinical trials expansions
2. Financial agreements
** Also, on the 20th of January, Kevin O’Leary and Jr Rahn went live discussing MindMed. For those who haven’t seen it, Jr mentioned a few extra catalysts we should be looking forward to which we will discuss in our next episode.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://www.prnewswire.com/news-releases/atai-life-sciences-announces-closing-of-125-million-series-c-financing-round-301178915.html
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF